|
1
|
Compston A and Coles A: Multiple
sclerosis. Lancet. 359:1221–1231. 2002.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bertolotto A: Neutralizing antibodies to
interferon beta: Implications for the management of multiple
sclerosis. Curr Opin Neurol. 17:241–246. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wingerchuk DM and Weinshenker BG: Disease
modifying therapies for relapsing multiple sclerosis. BMJ.
354(i3518)2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
PRISMS Study Group and the University of
British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term
efficacy of interferon-beta-1a in relapsing MS. Neurology.
56:1628–1636. 2001.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ebers GC: PRISM Study Group. Randomised
double-blind placebo-controlled study of interferon β-1a in
relapsing/remitting multiple sclerosis. PRISMS (Prevention of
Relapses and Disability by Interferon β-1a Subcutaneously in
Multiple Sclerosis) Study Group. Lancet. 352:1498–1504.
1998.PubMed/NCBI
|
|
6
|
Enevold C, Oturai AB, Sørensen PS, Ryder
LP, Koch-Henriksen N and Bendtzen K: Polymorphisms of innate
pattern recognition receptors, response to interferon-beta and
development of neutralizing antibodies in multiple sclerosis
patients. Mult Scler. 16:942–949. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
The IFNB Multiple Sclerosis Study Group
and the University of British Columbia MS/MRI Analysis Group.
Neutralizing antibodies during treatment of multiple sclerosis with
interferon beta-1b: Experience during the first three years.
Neurology. 47:889–894. 1996.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sorensen PS, Ross C, Clemmesen KM,
Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T,
Rasmussen S, Ravnborg M, et al: Danish Multiple Sclerosis Study
Group: Clinical importance of neutralising antibodies against
interferon beta in patients with relapsing-remitting multiple
sclerosis. Lancet. 362:1184–1191. 2003.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hedegaard CJ, Enevold C, Sellebjerg F,
Bendtzen K and Nielsen CH: Variation in NOD2 augments Th2- and Th17
responses to myelin basic protein in multiple sclerosis. PLoS One.
6(e20253)2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Enevold C, Oturai AB, Sørensen PS, Ryder
LP, Koch-Henriksen N and Bendtzen K: Multiple sclerosis and
polymorphisms of innate pattern recognition receptors TLR1-10,
NOD1-2, DDX58, and IFIH1. J Neuroimmunol. 212:125–131.
2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
McDonald WI, Compston A, Edan G, Goodkin
D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH,
Reingold SC, et al: Recommended diagnostic criteria for multiple
sclerosis: Guidelines from the International Panel on the diagnosis
of multiple sclerosis. Ann Neurol. 50:121–127. 2001.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Río J, Nos C, Tintoré M, Téllez N, Galán
I, Pelayo R, Comabella M and Montalban X: Defining the response to
interferon-beta in relapsing-remitting multiple sclerosis patients.
Ann Neurol. 59:344–352. 2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kurtzke JF: Rating neurologic impairment
in multiple sclerosis: An expanded disability status scale (EDSS).
Neurology. 33:1444–1452. 1983.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Howe KL, Achuthan P, Allen J, Allen J,
Alvarez-Jarreta J, Amode MR, Armean IM, Azov AG, Bennett R, Bhai J,
et al: Ensembl 2021. Nucleic Acids Res. 49:D884–D891.
2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Karolchik D, Baertsch R, Diekhans M, Furey
TS, Hinrichs A, Lu YT, Roskin KM, Schwartz M, Sugnet CW, Thomas DJ,
et al: The UCSC genome browser database. Nucleic Acids Res.
31:51–54. 2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Safran M, Dalah I, Alexander J, Rosen N,
Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, et al:
GeneCards Version 3: the human gene integrator. Database (Oxford).
2010(baq020)2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Farré D, Roset R, Huerta M, Adsuara JE,
Roselló L, Albà MM and Messeguer X: Identification of patterns in
biological sequences at the ALGGEN server: PROMO and MALGEN.
Nucleic Acids Res. 31:3651–3653. 2003.PubMed/NCBI View Article : Google Scholar
|
|
18
|
1000 Genomes Project Consortium. Abecasis
GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang
HM, Marth GT and McVean GA: An integrated map of genetic variation
from 1,092 human genomes. Nature. 491:56–65. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Xu Z and Taylor JA: SNPinfo: integrating
GWAS and candidate gene information into functional SNP selection
for genetic association studies. Nucleic Acids Res. 37 (Web Server
issue):W600–W605. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Court MH: A simple calculator to determine
whether observed genotype frequencies are consistent with
Hardy-Weinberg equilibrium. 2008. https://accounts.smccd.edu/case/biol215/docs/HW_calculator.xls.
|
|
21
|
Royal W III, Gartner S and Gajewski CD:
Retinol measurements and retinoid receptor gene expression in
patients with multiple sclerosis. Mult Scler. 8:452–458.
2002.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hoffmann S, Cepok S, Grummel V,
Lehmann-Horn K, Hackermüller J, Stadler PF, Hartung HP, Berthele A,
Deisenhammer F, Wassmuth R, et al: HLA-DRB1*0401 and HLA-DRB1*0408
are strongly associated with the development of antibodies against
interferon-beta therapy in multiple sclerosis. Am J Hum Genet.
83:219–227. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Buck D, Cepok S, Hoffmann S, Grummel V,
Jochim A, Berthele A, Hartung HP, Wassmuth R and Hemmer B:
Influence of the HLA-DRB1 genotype on antibody development to
interferon beta in multiple sclerosis. Arch Neurol. 68:480–487.
2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Barbosa MD, Vielmetter J, Chu S, Smith DD
and Jacinto J: Clinical link between MHC class II haplotype and
interferon-beta (IFN-beta) immunogenicity. Clin Immunol. 118:42–50.
2006.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Arellano G, Acuña E, Reyes LI, Ottum PA,
De Sarno P, Villarroel L, Ciampi E, Uribe-San Martín R, Cárcamo C
and Naves R: Th1 and Th17 cells and associated cytokines
discriminate among clinically isolated syndrome and multiple
sclerosis phenotypes. Front Immunol. 8(753)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Fagone P, Mazzon E, Cavalli E, Bramanti A,
Petralia MC, Mangano K, Al-Abed Y, Bramati P and Nicoletti F:
Contribution of the macrophage migration inhibitory factor
superfamily of cytokines in the pathogenesis of preclinical and
human multiple sclerosis: In silico and in vivo evidences. J
Neuroimmunol. 322:46–56. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Benedek G, Meza-Romero R, Jordan K, Zhang
Y, Nguyen H, Kent G, Li J, Siu E, Frazer J, Piecychna M, et al: MIF
and D-DT are potential disease severity modifiers in male MS
subjects. Proc Natl Acad Sci USA. 114:E8421–E8429. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Cavalli E, Mazzon E, Basile MS, Mammana S,
Pennisi M, Fagone P, Kalfin R, Martinovic V, Ivanovic J, Andabaka
M, et al: In silico and in vivo analysis of IL37 in multiple
sclerosis reveals its probable homeostatic role on the clinical
activity, disability, and treatment with fingolimod. Molecules.
25(20)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Fagone P, Patti F, Mangano K, Mammana S,
Coco M, Touil-Boukoffa C, Chikovani T, Di Marco R and Nicoletti F:
Heme oxygenase-1 expression in peripheral blood mononuclear cells
correlates with disease activity in multiple sclerosis. J
Neuroimmunol. 261:82–86. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Dujmovic I, Mangano K, Pekmezovic T,
Quattrocchi C, Mesaros S, Stojsavljevic N, Nicoletti F and Drulovic
J: The analysis of IL-1 beta and its naturally occurring inhibitors
in multiple sclerosis: The elevation of IL-1 receptor antagonist
and IL-1 receptor type II after steroid therapy. J Neuroimmunol.
207:101–106. 2009.PubMed/NCBI View Article : Google Scholar
|
